Merck & Co.Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Merck & Co. (MRK) reported revenue of $16.29B in Q1 2026, with Pharmaceutical its largest revenue segment at 88%.
Merck & Co.Diversified pharma anchored by Keytruda, vaccines, and animal health. Entered the obesity pill race in December 2024 by licensing Hansoh's oral small-molecule GLP-1 agonist HS-10535 for $112M upfront and up to $1.9B in milestones; that asset is still preclinical. Its clinical-stage metabolic asset is efinopegdutide, a weekly GLP-1/glucagon co-agonist in Phase 2b for MASH.
Q2 2024-Q1 2026
Q2 2024-Q1 2026
Q2 2024-Q1 2026
Merck & Co. (MRK) is a Drug Manufacturers - General company. Diversified pharma anchored by Keytruda, vaccines, and animal health. Entered the obesity pill race in December 2024 by licensing Hansoh's oral small-molecule GLP-1 agonist HS-10535 for $112M upfront and up to $1.9B in milestones; that asset is still preclinical. Its clinical-stage metabolic asset is efinopegdutide, a weekly GLP-1/glucagon co-agonist in Phase 2b for MASH. It was founded in 1891, is headquartered in Rahway, NJ and employs about 75,000 people.
As of 2026-Q1, Merck & Co.'s revenue breaks down across Pharmaceutical (88%), Animal Health (11%), Other Segments (1%). See the revenue-by-segment chart for the full mix.
Track Merck & Co.'s quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated July 30, 2026.
Sterling groups Merck & Co. in the GLP-1 sector, alongside Pfizer (PFE), Amgen (AMGN), Roche (RHHBY), AstraZeneca (AZN) and AbbVie (ABBV).
If you are researching Merck & Co., also look at Pfizer (PFE), Amgen (AMGN) and Roche (RHHBY). You can compare all of them side by side or browse the full GLP-1 sector on Sterling.